{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:45:56Z","timestamp":1784666756182,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study evaluated survival outcomes and prognostic factors in patients with bladder cancer treated with radiotherapy. A retrospective analysis was conducted on 488 patients across all cancer stages who received radiotherapy at two institutions between 1 January 2000 and 31 December 2022. Overall survival (OS) was assessed based on treatment intent (radical or palliative) and cancer stage. Among these patients, 304 with Stage II\u2013III disease who underwent radical radiotherapy were further analyzed for OS and prognostic factors using Kaplan\u2013Meier methods and Cox regression analysis. In the radical radiotherapy group, median survival times (MSTs) were 43\u00a0months for Stage 0\u2013I, 29\u00a0months for Stage II\u2013III, and 17\u00a0months for Stage IV (M0). In the palliative radiotherapy group, MSTs were 16\u00a0months (95% confidence interval [CI]: 11\u201325) for M0 and 9\u00a0months (95% CI: 7\u201315) for M1. Among the 304 patients with Stage II\u2013III disease treated with radical radiotherapy, the 3-year OS rate was 43.0%. Hydronephrosis was the only independent prognostic factor significantly associated with worse OS (hazard ratio: 1.915, P\u2009&amp;lt;\u20090.001). Age, sex, stage, treatment era, prophylactic pelvic radiotherapy, chemotherapy and prescribed dose had no significant impact on OS. Radiotherapy remains a viable treatment option for patients at any stage of cancer. Although hydronephrosis negatively affects survival, it should not preclude the use of radiotherapy.<\/jats:p>","DOI":"10.1093\/jrr\/rraf018","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T09:07:27Z","timestamp":1744621647000},"page":"272-279","source":"Crossref","is-referenced-by-count":2,"title":["Survival outcomes and prognostic factors in bladder cancer treated with radiotherapy"],"prefix":"10.1093","volume":"66","author":[{"given":"Koyo","family":"Kikuchi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibuki","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Prefectural Central Hospital , 1-4-1 Ueda, Morioka, Iwate 020-0066 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Segawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Prefectural Central Hospital , 1-4-1 Ueda, Morioka, Iwate 020-0066 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Ieko","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirobumi","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Radiology, Morioka Red Cross Hospital , 6-1-1 Sanbonyanagi, Morioka, Iwate 020-8560 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Ariga","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"2025052306515760500_ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025052306515760500_ref2","volume-title":"Cancer Information Service","author":"Cancer Statistics"},{"key":"2025052306515760500_ref3","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.3390\/cancers14246076","article-title":"Long-term projections of cancer incidence and mortality in Japan and decomposition analysis of changes in cancer burden, 2020-2054: an empirical validation approach","volume":"14","author":"Nguyen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025052306515760500_ref4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"2025052306515760500_ref5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semradonc.2022.10.003","article-title":"Pushing the envelope: the role of radiation therapy in non-muscle-invasive bladder cancer","volume":"33","author":"Kombathula","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"2025052306515760500_ref6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published correction appears in N Engl J Med. 2003;349:1880]","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"2025052306515760500_ref7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s00345-018-2384-6","article-title":"Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis","volume":"36","author":"Garc\u00eda-Perdomo","year":"2018","journal-title":"World J Urol"},{"key":"2025052306515760500_ref8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clgc.2018.09.023","article-title":"Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer","volume":"17","author":"Royce","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2025052306515760500_ref9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025052306515760500_ref10","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"key":"2025052306515760500_ref11","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 5.2024","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"2025052306515760500_ref12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00345-023-04744-x","article-title":"Radiotherapy in metastatic bladder cancer","volume":"42","author":"Ashley","year":"2024","journal-title":"World J Urol"},{"key":"2025052306515760500_ref13","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1016\/j.clgc.2019.01.009","article-title":"Contemporary survival rates for muscle-invasive bladder cancer treated with definitive or non-definitive therapy","volume":"17","author":"Gild","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2025052306515760500_ref14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jrr\/rraa039","article-title":"Modified Glasgow prognostic score can predict survival of muscle invasive bladder cancer patients after radiotherapy","volume":"61","author":"Kikuchi","year":"2020","journal-title":"J Radiat Res"},{"key":"2025052306515760500_ref15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely-available easy-to-use software \u201cEZR\u201d (easy R) for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"2025052306515760500_ref16","volume-title":"Cancer Facts & Figures 2024","author":"American Cancer Society","year":"2024"},{"key":"2025052306515760500_ref17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1590\/S1677-5538.IBJU.2021.0329","article-title":"Computed-tomography based scoring system predicts outcome for clinical lymph node-positive patients undergoing radical cystectomy","volume":"48","author":"Eismann","year":"2022","journal-title":"Int Braz J Urol"},{"key":"2025052306515760500_ref18","doi-asserted-by":"publisher","first-page":"195.e27","DOI":"10.1016\/j.urolonc.2022.01.002","article-title":"Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: a multicenter cohort from the European Association of Urology-Young Academic Urologists","volume":"40","author":"Lonati","year":"2022","journal-title":"Urol Oncol"},{"key":"2025052306515760500_ref19","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.ctro.2024.100866","article-title":"Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer","volume":"49","author":"Carriere","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"2025052306515760500_ref20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1590\/S1677-5538.IBJU.2013.06.06","article-title":"The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery","volume":"39","author":"Lacarri\u00e8re","year":"2013","journal-title":"Int Braz J Urol"},{"key":"2025052306515760500_ref21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijrobp.2020.11.068","article-title":"Clinical outcomes of a randomized trial of adaptive plan-of-the-day treatment in patients receiving ultra-hypofractionated weekly radiation therapy for bladder cancer","volume":"110","author":"Huddart","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025052306515760500_ref22","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"2025052306515760500_ref23","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025052306515760500_ref24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/jjco\/hyu129","article-title":"Patterns of practice in the radiation therapy for bladder cancer: survey of the Japanese Radiation Oncology Study Group (JROSG)","volume":"44","author":"Maebayashi","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"2025052306515760500_ref25","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.21873\/anticanres.11134","article-title":"Clinical results for bladder cancer treated by radiotherapy without concurrent standard chemotherapy","volume":"36","author":"Sakaguchi","year":"2016","journal-title":"Anticancer Res"},{"key":"2025052306515760500_ref26","doi-asserted-by":"publisher","first-page":"e0222223","DOI":"10.1371\/journal.pone.0222223","article-title":"Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: a meta-analysis","volume":"14","author":"Zhu","year":"2019","journal-title":"PLoS One"},{"key":"2025052306515760500_ref27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0022-5347(01)62228-6","article-title":"Hydronephrosis as a prognostic indicator in bladder cancer patients","volume":"160","author":"Haleblian","year":"1998","journal-title":"J Urol"},{"key":"2025052306515760500_ref28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0022-5347(01)65563-0","article-title":"Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy","volume":"156","author":"Chauvet","year":"1996","journal-title":"J Urol"},{"key":"2025052306515760500_ref29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/02841860410018629","article-title":"Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer","volume":"43","author":"Fokdal","year":"2004","journal-title":"Acta Oncol"},{"key":"2025052306515760500_ref30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.ju.0000072422.69286.0e","article-title":"Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density","volume":"170","author":"Stein","year":"2003","journal-title":"J Urol"},{"key":"2025052306515760500_ref31","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025052306515760500_ref32","doi-asserted-by":"publisher","first-page":"1269166","DOI":"10.3389\/fonc.2023.1269166","article-title":"Immune changes in hilar tumor draining lymph nodes following node sparing neoadjuvant chemoradiotherapy of localized cN0 non-small cell lung cancer","volume":"13","author":"Khalifa","year":"2023","journal-title":"Front Oncol"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/66\/3\/272\/62925039\/rraf018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/66\/3\/272\/62925039\/rraf018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:52:06Z","timestamp":1747997526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/66\/3\/272\/8113146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,14]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rraf018","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,14]]}}}